Gene · 26524
LATS2: large tumor suppressor kinase 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. LATS2: large tumor suppressor kinase 2. Genes, record 26524. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/26524
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9NRM7 | Serine/threonine-protein kinase LATS2 | 1,088 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents42
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 10569 | Q9NRM7 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 10927 | Q9NRM7 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 10927 | Q9NRM7 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 10569 | Q9NRM7 | Espacenet |
| US 12268704 B2 | 2025-04-08 | 4 | Q9NRM7 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 6799 | Q9NRM7 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 6800 | Q9NRM7 | Espacenet |
| JP 2023522784 A | 2023-05-31 | 167 | Q9NRM7 | Espacenet |
| JP 2022188056 A | 2022-12-20 | 3 | Q9NRM7 | Espacenet |
| US 11458138 B2 | 2022-10-04 | 3 | Q9NRM7 | Espacenet |
1 to 10 of 42
See all 42 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,439
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | LATS2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 28 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 24 | 2025 |
| P30DK026743 | UCSF Liver Center | 7 | 2025 |
| P30CA036727 | Buffett Cancer Center Support Grant | 6 | 2025 |
| R01HL118761 | Pitx2 in atrial fibrillation | 6 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 5 | 2025 |
| P30DK034854 | Integrated Epithelial and Muscosal Biology | 5 | 2025 |
| R01EY015708 | Control of Cell Number in Developing Retina | 5 | 2025 |
| R01GM126048 | Regulation and function of the Hippo pathway in growth control | 5 | 2025 |
| P30CA014051 | Cancer Center Support (Core) Grant | 4 | 2025 |
1 to 10 of 1,439Source NIH's project files
See all 1,439 nih grantsPapers2,966
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comparing YAPWW1 and TAZWW: Similar Binding Sites but Different Stability and Conformational Dynamics. | Biomolecules | 2026 | 42793187 | PubTator, text mining | PubMed |
| LATS1/2 inactivation drives a distinct venous endothelial cell response that contributes to fibrotic remodeling of the lung. | Sci Adv | 2026 | 42664350 | PubTator, text mining | PubMed |
| Enzymatic activity-independent NANS stabilizes LATS2 to drive growth and therapeutic resistance in HR+/HER2- breast cancer. | Nat Commun | 2026 | 42642385 | PubTator, text mining | PubMed |
| Yorkie/YAP Interactors: Fine-Tuning the Hippo Pathway Output. | Cold Spring Harb Perspect Biol | 2026 | 42575696 | PubTator, text mining | PubMed |
| Transcription factor activity profiling uncovers prognostic subtypes and a novel oncogenic role for PRDM4 in NSMP endometrial carcinoma. | BMC Cancer | 2026 | 42471606 | PubTator, text mining | PubMed |
| Ribosomal RNA transcription is regulated by sequestration of LATS2 and PHF6 to the nuclear speckles following DNA damage. | J Cell Sci | 2026 | 42421490 | PubTator, text mining | PubMed |
| A human iPSC model with LATS1/2 knockdown (MUSIi012-A-9) for investigating Hippo signaling in stem cell. | Stem Cell Res | 2026 | 42378908 | PubTator, text mining | PubMed |
| TEAD1 condensates are transcriptionally inactive storage sites on the pericentromeric heterochromatin in cancer cells. | Nat Cell Biol | 2026 | 42277434 | PubTator, text mining | PubMed |
| LATS2 expression differences in lung adenocarcinoma and lung squamous cell carcinoma analyzed using bioinformatics and experimental approaches. | Oncol Lett | 2026 | 42272771 | PubTator, text mining | PubMed |
| MITF maintains genome stability in nonmelanocyte lineages. | Mol Oncol | 2026 | 42268265 | PubTator, text mining | PubMed |
1 to 10 of 2,966
See all 2,966 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/26524
GET https://conductscience.org/api/genes/v1/26524/patents?page=2